Immunic, Inc.
NASDAQ Global SelectTotal Valuation
Immunic, Inc. carries a market capitalization of 178.58M, placing it among publicly traded companies globally. Its enterprise value stands at -35.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 178.58M |
| Enterprise Value | -35.01M |
Share Statistics
Immunic, Inc. currently has 13.62M shares outstanding.
| Shares Outstanding | 13.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | -2.86 |
| P/OCF Ratio | -2.85 |
Financial Position
Immunic, Inc. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.92 |
| Quick Ratio | 4.87 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -607.42 |
| Return on Assets (ROA) | -99.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Immunic, Inc.'s stock has gained approximately 70.25974% over the past 52 weeks. The 50-day moving average sits at 15.01, while the 200-day moving average is 10.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | 70.25974% |
| 50-Day Moving Average | 15.01 |
| 200-Day Moving Average | 10.99 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -109.48M, while operating income came in at -109.64M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -109.64M |
| Pretax Income | -104.29M |
| Net Income | -104.29M |
| EBITDA | -109.48M |
| EBIT | -109.64M |
| Earnings Per Share (EPS) | -4.99 |
Balance Sheet
Immunic, Inc. holds 186.63M in cash and equivalents against 421,000.00 in total debt, resulting in a net debt position of -186.63M. Total book value stands at 151.23M, with working capital of 150.40M providing operational flexibility.
| Cash & Cash Equivalents | 186.63M |
| Total Debt | 421,000.00 |
| Net Debt | -186.63M |
| Equity (Book Value) | 151.23M |
| Book Value Per Share | 11.10 |
| Working Capital | 150.40M |
Cash Flow
Immunic, Inc. produced -81.33M in operating cash flow over the past twelve months. After subtracting -116,000.00 in capital expenditures, free cash flow totaled -81.45M - equivalent to -3.89 per share.
| Operating Cash Flow | -81.33M |
| Capital Expenditures | -116,000.00 |
| Free Cash Flow | -81.45M |
| FCF Per Share | -3.89 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -168.14 |
| FCF Yield | -34.98 |
Stock Splits
Immunic, Inc.'s most recent stock split took place on April 27, 2026 with a 10:1 split ratio.
| Last Split Date | 4/27/2026 |
| Split Ratio | 10:1 |
Scores
Immunic, Inc. posts an Altman Z-Score of -3.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.33 |